Mouse Model Demonstrates Potential of New Autism Drug | Technology Networks
NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model - ScienceDirect
The BRAIN Foundation - Potential of MEF2 Transcriptional Activator Therapy for ASD Phenotypes - STUART LIPTON, MD, PhD Hannah and Eugene Step Chair; Professor; Co-director, Neuroscience Translational Center Department of Molecular Medicine,
NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model - ScienceDirect
Researchers are Testing a New Medicine That Could Reduce Anxiety and Other Autism Challenges - The Autism Site News
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism | Nature Communications
Mouse Model Demonstrates Potential of New Autism Drug | Technology Networks
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism | Nature Communications
NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model - ScienceDirect
Aberrant gliogenesis and excitation in MEF2C autism patient hiPSC-neurons and cerebral organoids | bioRxiv
PDF) NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism
In human mini-brain experiments, drug preserves and rebuilds nerve connections that are lost to Alzheimer's | Scripps Research
Human Neurons from Ctrl- and AD-Patient-Derived iPSCs Are Resistant to... | Download Scientific Diagram